Showing 281 - 300 results of 33,895 for search '(( 50 ((((ng decrease) OR (we decrease))) OR (a decrease)) ) OR ( e non decrease ))', query time: 1.02s Refine Results
  1. 281

    ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

    Published 2022
    “…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”
  2. 282
  3. 283
  4. 284
  5. 285
  6. 286
  7. 287
  8. 288
  9. 289
  10. 290

    Distribution Coefficients of the REEs, Sr, Y, Ba, Th, and U between α‑HIBA and AG50W-X8 Resin by Haoyu Li (1672648)

    Published 2020
    “…For all 19 elements, the distribution coefficients decrease with increasing acid concentration. For the REEs, a linear relationship is observed in log–log space between <i>K</i><sub>d</sub> values and α-HIBA molarity. …”
  11. 291
  12. 292
  13. 293

    Table_1_Gomisin A Suppresses Colorectal Lung Metastasis by Inducing AMPK/p38-Mediated Apoptosis and Decreasing Metastatic Abilities of Colorectal Cancer Cells.DOC by Ji-Ye Kee (4011965)

    Published 2018
    “…A non-cytotoxic concentration of G.A inhibited epithelial–mesenchymal transition of CRC cells by modulating E-cadherin and N-cadherin expression levels. …”
  14. 294

    Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

    Published 2024
    “…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”
  15. 295
  16. 296
  17. 297
  18. 298
  19. 299
  20. 300

    Prognosis and risk factors of chronic kidney disease progression in patients with diabetic kidney disease and non-diabetic kidney disease: a prospective cohort CKD-ROUTE study by Shengnan Chen (3595319)

    Published 2022
    “…The secondary endpoints were all-cause death and the development of cardiovascular disease (CVD) events. We found that DKD patients have a higher risk to develop 50% eGFR decline endpoint (HR:2.30, 95%CI [1.48–3.58], <i>p</i> < 0.001) and KRT endpoint (HR:1.64, 95%CI [1.13–2.37], <i>p</i> < 0.05) than NDKD patients. …”